Dekker ET, Tanis PJ, Vleugels JLA, Kasi PM, Wallace M. Colorectal most cancers. Lancet. 2019;394(10207):1467–80.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. World most cancers statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J Clin. 2021;71(3):209–49.
Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal most cancers statistics, 2020. CA Most cancers J Clin. 2020;70(3):145–64.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus mixture chemotherapy with capecitabine, irinotecan, and oxaliplatin in superior colorectal most cancers (CAIRO): a part III randomised managed trial. Lancet. 2007;370(9582):135–42.
Kaczor A, Nove M, Kincses A, Spengler G, Szymanska E, Latacz G, et al. Seek for ABCB1 modulators amongst 2-amine-5-arylideneimidazolones as a brand new perspective to beat most cancers multidrug resistance. Molecules. 2020;25(9):2258.
Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine mixture remedy for colorectal most cancers (SCOT): a world, randomised, part 3, non-inferiority trial. Lancet Oncol. 2018;19(4):562–78.
Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line mixture chemotherapy for therapy of superior colorectal most cancers: outcomes of the randomised part 3 MRC COIN trial. Lancet. 2011;377(9783):2103–14.
Desrame J, Broustet H, de Tailly PD, Girard D, Saissy JM. Oxaliplatin-induced haemolytic anaemia. Lancet. 1999;354(9185):1179–80.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo together with second-line FOLFIRI in sufferers with metastatic colorectal carcinoma that progressed throughout or after first-line remedy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, part 3 examine. Lancet Oncol. 2015;16(5):499–508.
Chen M, Liang X, Gao C, Zhao R, Zhang N, Wang S, et al. Ultrasound triggered conversion of porphyrin/camptothecin-fluoroxyuridine triad microbubbles into nanoparticles overcomes multidrug resistance in colorectal most cancers. ACS Nano. 2018;12(7):7312–26.
Liu B, Xu T, Xu X, Cui Y, Xing X. Biglycan promotes the chemotherapy resistance of colon most cancers by activating NF-kappaB sign transduction. Mol Cell Biochem. 2018;449(1–2):285–94.
Wesolowska O, Michalak Okay, Blaszczyk M, Molnar J, Sroda-Pomianek Okay. Organosilicon compounds, SILA-409 and SILA-421, as doxorubicin resistance-reversing brokers in human colon most cancers cells. Molecules. 2020;25(7):1654.
Chen D, Ge S, Zuo L, Wang S, Liu M, Li S. Adjudin-loaded redox-sensitive paclitaxel-prodrug micelles for overcoming multidrug resistance with environment friendly focused Colon most cancers remedy. Drug Deliv. 2020;27(1):1094–105.
Salustiano EJ, da Costa KM, Freire-de-Lima L, Mendonca-Previato L, Previato JO. Inhibition of glycosphingolipid biosynthesis reverts multidrug resistance by differentially modulating ABC transporters in power myeloid leukemias. J Biol Chem. 2020;295(19):6457–71.
Nayak D, Tripathi N, Kathuria D, Siddharth S, Nayak A, Bharatam PV, et al. Quinacrine and curcumin synergistically elevated the breast most cancers stem cells demise by inhibiting ABCG2 and modulating DNA injury restore pathway. Int J Biochem Cell Biol. 2020;119: 105682.
Madrid-Paredes A, Casado-Combreras MA, Perez-Ramirez C, Segura-Perez AM, Chamorro-Santos C, Vergara-Alcalde E, et al. Affiliation of ABCB1 and VEGFA gene polymorphisms with breast most cancers susceptibility and prognosis. Pathol Res Pract. 2020;216(4): 152860.
Lu X, Wang Z, Huang H, Wang H. Hedgehog signaling promotes multidrug resistance by regulation of ABC transporters in oral squamous cell carcinoma. J Oral Pathol Med. 2020;49(9):897–906.
Ethical JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, et al. ILC2s amplify PD-1 blockade by activating tissue-specific most cancers immunity. Nature. 2020;579(7797):130–5.
Gao Y, Nihira NT, Bu X, Chu C, Zhang JF, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22(9):1064–75.
Zuazo M, Arasanz H, Bocanegra A, Chocarro L, Vera R, Escors D, et al. Systemic CD4 immunity: a robust scientific biomarker for PD-L1/PD-1 immunotherapy. EMBO Mol Med. 2020;12(9): e12706.
Zou S, Liu J, Solar Z, Feng X, Wang Z, Jin Y, et al. Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interplay by means of in silico proteolysis and rational design. Most cancers Chemother Pharmacol. 2020;85(1):185–93.
Litton JK, Laird D, Rugo HS, Ettl J, Hurvitz SA, Martin M, et al. Exploring impression of mutations in non-BRCA DNA injury response (DDR) and non-DDR genes on efficacy in part III EMBRACA examine of talazoparib (TALA) in sufferers (pts) with germline BRCA1/2 mutated (gBRCAm) HER2-negative (HER2-) superior breast most cancers (ABC). J Clin Oncol. 2020;38(15):1018.
Li S, Chen Q, Gong X, Liu Y, Zheng F. RanB, a putative ABC-type multidrug efflux transporter contributes to aminoglycosides resistance and natural solvents tolerance in Riemerella anatipestifer. Vet Microbiol. 2020;243: 108641.
Hanahan D, Weinberg RA. Hallmarks of most cancers: the following era. Cell. 2011;144(5):646–74.
Ribas A, Wolchok JD. Most cancers immunotherapy utilizing checkpoint blockade. Science. 2018;359(6382):1350–5.
Gao Q, Li XX, Xu YM, Zhang JZ, Rong SD, Qin YQ, et al. IRE1alpha-targeting downregulates ABC transporters and overcomes drug resistance of colon most cancers cells. Most cancers Lett. 2020;476:67–74.
Li W, Zhang H, Assaraf YG, Zhao Okay, Xu X, Xie J, et al. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug methods. Drug Resist Updat. 2016;27:14–29.
Kachalaki S, Ebrahimi M, Mohamed Khosroshahi L, Mohammadinejad S, Baradaran B. Most cancers chemoresistance; biochemical and molecular features: a quick overview. Eur J Pharm Sci. 2016;89:20–30.
Zhang GN, Gupta P, Wang M, Barbuti AM, Ashby CR Jr, Zhang YK, et al. Lipid-saporin nanoparticles for the intracellular supply of cytotoxic protein to beat ABC transporter-mediated multidrug resistance in vitro and in vivo. Cancers (Basel). 2020;12(2):498.
Hasanovic A, Mus-Veteau I. Concentrating on the multidrug transporter Ptch1 potentiates chemotherapy effectivity. Cells. 2018;7(8):107.
Liu Z, Liu Y, Lengthy Y, Liu B, Wang X. Position of HSP27 within the multidrug sensitivity and resistance of colon most cancers cells. Oncol Lett. 2020;19(3):2021–7.
Yang Okay, Chen Y, To KKW, Wang F, Li D, Chen L, et al. Correction: Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro, in vivo and ex vivo. Exp Mol Med. 2020;52(6):989–90.
Wu ZX, Yang Y, Wang G, Wang JQ, Teng QX, Solar L, et al. Twin TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung most cancers cells. Most cancers Sci. 2020;111(8):2872–82.
Mfg B, Spc D, Uf MJ. Overcoming multidrug resistance: flavonoid and terpenoid nitrogen-containing derivatives as ABC transporter modulators. Molecules. 2020;25(15):3364.
Wang B, Wu S, Lin Z, Jiang Y, Chen Y, Chen ZS, et al. A customized and long-acting native therapeutic platform combining photothermal remedy and chemotherapy for the therapy of multidrug-resistant colon tumor. Int J Nanomed. 2018;13:8411–27.
Hu J, Jiang Y, Tan S, Zhu Okay, Cai T, Zhan T, et al. Selenium-doped calcium phosphate biomineral reverses multidrug resistance to boost bone tumor chemotherapy. Nanomedicine. 2021;32: 102322.
Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, et al. Twin ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung most cancers. Lung Most cancers. 2014;83(1):37–43.
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, et al. Focused inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung most cancers. Most cancers Discov. 2013;3(4):430–43.
Liu F, Cao L, Zhang Y, Xia X, Ji Y. LncRNA LIFR-AS1 overexpression suppressed the development of serous ovarian carcinoma. J Clin Lab Anal. 2022;36(8): e25470.
Chen Q, Liu T, Chen S, Luo Y, Ma M, Xue F, et al. Focused therapeutic-immunomodulatory nanoplatform based mostly on noncrystalline selenium. ACS Appl Mater Interfaces. 2019;11(49):45404–15.
Tang Z, Liu Y, He M, Bu W. Chemodynamic remedy: tumour microenvironment-mediated fenton and fenton-like reactions. Angew Chem Int Ed Engl. 2019;58(4):946–56.
Woynarowski JMFS, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE. Oxaliplatin-induced injury of mobile DNA. Mol Pharmacol. 2000;58(5):920–7.
Li L, Zhu Y, Liu M, Jin D, Zhang L, Cheng J, et al. Conjugation of oxaliplatin with PEGylated-nanobody for enhancing tumor concentrating on and prolonging circulation. J Inorg Biochem. 2021;223: 111553.
Wang X, Li M, Ren Okay, Xia C, Li J, Yu Q, et al. On-demand autophagy cascade amplification nanoparticles exactly enhanced oxaliplatin-induced most cancers immunotherapy. Adv Mater. 2020;32(32): e2002160.
Yang Y, Zhao B, Gao X, Solar J, Ye J, Li J, et al. Concentrating on methods for oxaliplatin-induced peripheral neuropathy: scientific syndrome, molecular foundation, and drug growth. J Exp Clin Most cancers Res. 2021;40(1):331.
Taib S, Durand J, Brunet I. Oxaliplatin-induced peripheral neuropathy: methods to create a barrier? Med Sci (Paris). 2020;36 Hors serie n levels:33–7.
Calls A, Carozzi V, Navarro X, Monza L, Bruna J. Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical research. Exp Neurol. 2020;325: 113141.
Lin LS, Tune J, Tune L, Ke Okay, Liu Y, Zhou Z, et al. Simultaneous fenton-like ion supply and glutathione depletion by MnO2-based nanoagent to boost chemodynamic remedy. Angew Chem Int Ed Engl. 2018;57(18):4902–6.
Zhang D-Y, Liu H, Younis MR, Lei S, Chen Y, Huang P, et al. In-situ TiO2-x ornament of titanium carbide MXene for picture/sono-responsive antitumor theranostics. J Nanobiotechnol. 2022. https://doi.org/10.1186/s12951-022-01253-8.
Feng Y, Liu Y, Ma X, Xu L, Ding D, Chen L, et al. Intracellular marriage of bicarbonate and Mn ions as “immune ion reactors” to control redox homeostasis and enhanced antitumor immune responses. J Nanobiotechnol. 2022;20(1):193.
Sarin L, Sanchez VC, Yan A, Kane AB, Harm RH. Selenium-carbon bifunctional nanoparticles for the therapy of malignant mesothelioma. Adv Mater. 2010;22(45):5207–11.
Kong L, Yuan Q, Zhu H, Li Y, Guo Q, Wang Q, et al. The suppression of prostate LNCaP most cancers cells progress by Selenium nanoparticles by means of Akt/Mdm2/AR managed apoptosis. Biomaterials. 2011;32(27):6515–22.
Kong LYQ, Zhu H, Li Y, Guo Q, Wang Q, Bi X, Gao X. The suppression of prostate LNCaP most cancers cells progress by Selenium nanoparticles by means of Akt/Mdm2/AR managed apoptosis. Biomaterials. 2011;32(27):6515–22.
Guo CH, Hsia S, Chung CH, Lin YC, Shih MY, Chen PC, et al. Mixture of fish oil and selenium enhances anticancer efficacy and targets a number of signaling pathways in anti-VEGF agent treated-TNBC tumor-bearing mice. Mar Medicine. 2021;19(4):193.
Wang Z, Shen J, Solar W, Zhang T, Zuo D, Wang H, et al. Antitumor exercise of Raddeanin A is mediated by Jun amino-terminal kinase activation and sign transducer and activator of transcription 3 inhibition in human osteosarcoma. Most cancers Sci. 2019;110(5):1746–59.
Miki H, Uehara N, Kimura A, Sasaki T, Yuri T, Yoshizawa Okay, et al. Resveratrol induces apoptosis through ROS-triggered autophagy in human colon most cancers cells. Int J Oncol. 2012;40(4):1020–8.
To KK, Poon DC, Wei Y, Wang F, Lin G, Fu LW. Vatalanib sensitizes ABCB1 and ABCG2-overexpressing multidrug resistant colon most cancers cells to chemotherapy beneath hypoxia. Biochem Pharmacol. 2015;97(1):27–37.
Matsunaga T, Okumura N, Saito H, Morikawa Y, Suenami Okay, Hisamatsu A, et al. Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in achieve of irinotecan resistance in colon most cancers cells. Chem Biol Work together. 2020;332: 109295.
Chen T, Wong YS. Selenocystine induces apoptosis of A375 human melanoma cells by activating ROS-mediated mitochondrial pathway and p53 phosphorylation. Cell Mol Life Sci. 2008;65(17):2763–75.
Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy medication induce pyroptosis by means of caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99–103.
Lopez-Otin C, Hunter T. The regulatory crosstalk between kinases and proteases in most cancers. Nat Rev Most cancers. 2010;10(4):278–92.
Cheng R, Jiang L, Gao H, Liu Z, Makila E, Wang S, et al. A pH-responsive cluster metal-organic framework nanoparticle for enhanced tumor accumulation and antitumor impact. Adv Mater. 2022;34(42):e2203915.
Zou Y, Wang Y, Xu S, Liu Y, Yin J, Lovejoy DB, et al. Mind co-delivery of temozolomide and cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater. 2022;34(33): e2203958.
Zhou J, Lin Z, Ju Y, Rahim MA, Richardson JJ, Caruso F. Polyphenol-mediated meeting for particle engineering. Acc Chem Res. 2020;53(7):1269–78.
